Dr Marcus Yeo - Definigen

Dr Marcus Yeo

Chief Executive Officer

Dr Marcus Yeo is a founder and CEO of the company. He is an experienced Company Director and life scientist who took the Oxford-based diagnostics biotechnology company Cybersense Biosystems Ltd to acquisition in by the FTSE 100 company Severn Trent. He oversaw the integration of the business into the Severn Trent ISO 17025 structure and led sales and marketing of the Severn Trent analytics division. Marcus previously worked for the University of Oxford company Zyoxel Ltd (now CN Bio Innovations), which markets advanced 3D human tissue culture systems to the investigative toxicology drug discovery sector. He specialised in the development of next-generation stem cell derived liver toxicology products and disease modelling systems for drug discovery lead optimisation. He has a PhD in Molecular Biology and is an accredited European Commission Technology Expert who has coordinated major EU funded technology programmes.

Dr Marcus Yeo, Chief Executive Officer of DefiniGEN